Published in PLoS One on December 20, 2006
A genome-wide proteome array reveals a limited set of immunogens in natural infections of humans and white-footed mice with Borrelia burgdorferi. Infect Immun (2008) 2.15
Inhibition of ABC transporters abolishes antimony resistance in Leishmania Infection. Antimicrob Agents Chemother (2007) 1.15
Improved canine and human visceral leishmaniasis immunodiagnosis using combinations of synthetic peptides in enzyme-linked immunosorbent assay. PLoS Negl Trop Dis (2012) 1.01
Immunoproteomic analysis of the development of natural immunity in subjects colonized by Neisseria meningitidis reveals potential vaccine candidates. Infect Immun (2009) 0.94
rKLO8, a novel Leishmania donovani - derived recombinant immunodominant protein for sensitive detection of visceral leishmaniasis in Sudan. PLoS Negl Trop Dis (2013) 0.91
Vaccine Development Against Leishmania donovani. Front Immunol (2012) 0.90
Proteome serological determination of tumor-associated antigens in melanoma. PLoS One (2009) 0.86
Two-dimensional difference gel electrophoresis (DIGE) analysis of sera from visceral leishmaniasis patients. Clin Proteomics (2011) 0.85
Single dose novel Salmonella vaccine enhances resistance against visceralizing L. major and L. donovani infection in susceptible BALB/c mice. PLoS Negl Trop Dis (2011) 0.83
Heterogeneity of Leishmania donovani parasites complicates diagnosis of visceral leishmaniasis: comparison of different serological tests in three endemic regions. PLoS One (2015) 0.83
Biomarkers of safety and immune protection for genetically modified live attenuated leishmania vaccines against visceral leishmaniasis - discovery and implications. Front Immunol (2014) 0.82
Proteome-based analysis of serologically defined tumor-associated antigens in cutaneous lymphoma. PLoS One (2009) 0.81
A search for Trypanosoma brucei rhodesiense diagnostic antigens by proteomic screening and targeted cloning. PLoS One (2010) 0.79
Proteome profiling of human cutaneous leishmaniasis lesion. J Invest Dermatol (2014) 0.78
Immunodominant antigens of Leishmania chagasi associated with protection against human visceral leishmaniasis. PLoS Negl Trop Dis (2012) 0.78
Kinetoplastid genomics: the thin end of the wedge. Infect Genet Evol (2008) 0.77
An Optimized Fluorescence-Based Bidimensional Immunoproteomic Approach for Accurate Screening of Autoantibodies. PLoS One (2015) 0.76
The Leishmania infantum PUF proteins are targets of the humoral response during visceral leishmaniasis. BMC Res Notes (2010) 0.76
Identification of Immunoreactive Leishmania infantum Protein Antigens to Asymptomatic Dog Sera through Combined Immunoproteomics and Bioinformatics Analysis. PLoS One (2016) 0.76
Pathogenicity of Leishmania donovani is associated with the high expression of a group low molecular weight proteins. Trop Parasitol (2015) 0.75
Identification of Leishmania donovani antigen in circulating immune complexes of visceral leishmaniasis subjects for diagnosis. PLoS One (2017) 0.75
Drug resistance in leishmaniasis. Clin Microbiol Rev (2006) 7.35
Mass spectrometric identification of proteins from silver-stained polyacrylamide gel: a method for the removal of silver ions to enhance sensitivity. Electrophoresis (1999) 3.71
Multiplication of a human parasite (Leishmania donovani) in phagolysosomes of hamster macrophages in vitro. Science (1976) 3.55
Drug resistance in Indian visceral leishmaniasis. Trop Med Int Health (2001) 3.08
Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major. J Exp Med (1997) 2.81
The current state of two-dimensional electrophoresis with immobilized pH gradients. Electrophoresis (1988) 2.41
SL trans-splicing: easy come or easy go? Trends Genet (2005) 2.21
Second-generation vaccines against leishmaniasis. Trends Parasitol (2005) 1.99
Development of a safe live Leishmania vaccine line by gene replacement. Proc Natl Acad Sci U S A (1995) 1.99
The major surface protease (MSP or GP63) of Leishmania sp. Biosynthesis, regulation of expression, and function. Mol Biochem Parasitol (2003) 1.93
Oral Salmonella typhimurium (AroA-) vaccine expressing a major leishmanial surface protein (gp63) preferentially induces T helper 1 cells and protective immunity against leishmaniasis. J Immunol (1990) 1.90
Autoclaved Leishmania major vaccine for prevention of visceral leishmaniasis: a randomised, double-blind, BCG-controlled trial in Sudan. Lancet (2000) 1.86
The immunobiology of leishmaniasis. Rev Infect Dis (1983) 1.76
Rapid, noninvasive diagnosis of visceral leishmaniasis in India: comparison of two immunochromatographic strip tests for detection of anti-K39 antibody. J Clin Microbiol (2006) 1.75
Probabilistic order in antigenic variation of Trypanosoma brucei. Int J Parasitol (2005) 1.49
Identification and characterisation of a Leishmania donovani antigen belonging to the 70-kDa heat-shock protein family. Eur J Biochem (1990) 1.42
Induction of a Th1 immune response and simultaneous lack of activation of a Th2 response are required for generation of immunity to leishmaniasis. J Immunol (1998) 1.32
Regulation of innate and acquired immunity in African trypanosomiasis. Parasite Immunol (2005) 1.30
Vaccination with plasmid DNA encoding TSA/LmSTI1 leishmanial fusion proteins confers protection against Leishmania major infection in susceptible BALB/c mice. Infect Immun (2002) 1.25
A computational investigation of kinetoplastid trans-splicing. Genome Biol (2005) 1.23
The central roles of telomeres and subtelomeres in antigenic variation in African trypanosomes. Chromosome Res (2005) 1.21
Evolutionarily conserved proteins as prominent immunogens during Leishmania infections. Parasitol Today (2000) 1.21
Immune responses of leishmaniasis patients to heat shock proteins of Leishmania species and humans. Infect Immun (1995) 1.20
Plasmodium falciparum antigenic variation: relationships between in vivo selection, acquired antibody response, and disease severity. J Infect Dis (2005) 1.14
A protective cocktail vaccine against murine cutaneous leishmaniasis with DNA encoding cysteine proteinases of Leishmania major. Vaccine (2001) 1.14
Evaluation of the direct agglutination test and the rK39 dipstick test for the sero-diagnosis of visceral leishmaniasis. Mem Inst Oswaldo Cruz (2002) 1.13
Human T cell responses to gp63, a surface antigen of Leishmania. J Immunol (1991) 1.12
Recombinant vaccinia viruses expressing GP46/M-2 protect against Leishmania infection. Infect Immun (1993) 1.12
Within-host dynamics of antigenic variation. Infect Genet Evol (2006) 1.11
Visceral leishmaniasis in the New World & Africa. Indian J Med Res (2006) 1.11
Malaria: immune evasion by parasites. Int J Biochem Cell Biol (2005) 1.09
Host immunity modulates transcriptional changes in a multigene family (yir) of rodent malaria. Mol Microbiol (2005) 1.04
Parasite immune escape: new views into host-parasite interactions. Curr Opin Microbiol (2005) 1.03
The Leishmania donovani lipophosphoglycan T lymphocyte-reactive component is a tightly associated protein complex. J Immunol (1991) 1.03
DNA vaccination with linear minimalistic (MIDGE) vectors confers protection against Leishmania major infection in mice. Vaccine (2002) 0.98
Antigens shared by Leishmania species and Trypanosoma cruzi: immunological comparison of the acidic ribosomal P0 proteins. Infect Immun (1994) 0.97
The life-cycle of Leishmania in the sandfly with special reference to the form infective to the vertebrate host. Ann Parasitol Hum Comp (1990) 0.96
Trypanosomes expressing a mosaic variant surface glycoprotein coat escape early detection by the immune system. Infect Immun (2005) 0.93
Protection against Leishmania donovani infection by DNA vaccination: increased DNA vaccination efficiency through inhibiting the cellular p53 response. Vaccine (2001) 0.92
Immunoproteomics. Methods Mol Med (2004) 0.90
Molecular and immunological characterisation of the glucose regulated protein 78 of Leishmania donovani(1). Biochim Biophys Acta (2001) 0.89
Vaccination with DNA encoding ORFF antigen confers protective immunity in mice infected with Leishmania donovani. Vaccine (2003) 0.87
Visceral leishmaniasis in clinical practice. J Infect (1999) 0.87
Sequit: software for de novo peptide sequencing by matrix-assisted laser desorption/ionization post-source decay mass spectrometry. Rapid Commun Mass Spectrom (2004) 0.83
Inducible expression of suicide genes in Leishmania donovani amastigotes. J Biol Chem (1998) 0.83
Humoral and cellular immune responses to glucose regulated protein 78 -- a novel Leishmania donovani antigen. Trop Med Int Health (2002) 0.82
Sero-epidemiological study of kala-azar in a village of Varanasi district, India. Trop Med Int Health (2006) 0.80
Immobiline-based two-dimensional gel electrophoresis: an optimised protocol for resolution of human colonic mucosal proteins. Electrophoresis (1999) 0.80
Identification of new antigens in visceral leishmaniasis by expression cloning and immunoblotting with sera of kala-azar patients from Bihar, India. Infect Immun (2005) 0.79
More panantigens in Leishmania. Trends Parasitol (2001) 0.77
Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? Nat Rev Microbiol (2007) 7.36
Drug resistance in leishmaniasis. Clin Microbiol Rev (2006) 7.35
Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda. Lancet Infect Dis (2002) 7.17
Splenic accumulation of IL-10 mRNA in T cells distinct from CD4+CD25+ (Foxp3) regulatory T cells in human visceral leishmaniasis. J Exp Med (2007) 2.75
Phase 4 trial of miltefosine for the treatment of Indian visceral leishmaniasis. J Infect Dis (2007) 2.74
Visceral leishmaniasis elimination programme in India, Bangladesh, and Nepal: reshaping the case finding/case management strategy. PLoS Negl Trop Dis (2009) 2.56
Leishmaniasis: new approaches to disease control. BMJ (2003) 2.30
Longlasting insecticidal nets for prevention of Leishmania donovani infection in India and Nepal: paired cluster randomised trial. BMJ (2010) 2.30
Whole genome sequencing of multiple Leishmania donovani clinical isolates provides insights into population structure and mechanisms of drug resistance. Genome Res (2011) 2.21
Visceral leishmaniasis: elimination with existing interventions. Lancet Infect Dis (2011) 2.19
Liposomal amphotericin B for the treatment of visceral leishmaniasis. Clin Infect Dis (2006) 2.17
High incidence of zidovudine induced anaemia in HIV infected patients in eastern India. Indian J Med Res (2010) 2.11
Treatment options for visceral leishmaniasis: a systematic review of clinical studies done in India, 1980-2004. Lancet Infect Dis (2005) 2.06
Virgin soil: the spread of visceral leishmaniasis into Uttar Pradesh, India. Am J Trop Med Hyg (2005) 1.96
Diagnosis of visceral leishmaniasis. Trans R Soc Trop Med Hyg (2010) 1.93
Drug uptake and modulation of drug resistance in Leishmania by an aquaglyceroporin. J Biol Chem (2004) 1.79
Leishmania donovani targets Dicer1 to downregulate miR-122, lower serum cholesterol, and facilitate murine liver infection. Cell Host Microbe (2013) 1.77
Effectiveness and feasibility of active and passive case detection in the visceral leishmaniasis elimination initiative in India, Bangladesh, and Nepal. Am J Trop Med Hyg (2010) 1.74
Use of antimony in the treatment of leishmaniasis: current status and future directions. Mol Biol Int (2011) 1.71
Incidence of symptomatic and asymptomatic Leishmania donovani infections in high-endemic foci in India and Nepal: a prospective study. PLoS Negl Trop Dis (2011) 1.67
Visceral leishmaniasis in the Indian subcontinent: modelling epidemiology and control. PLoS Negl Trop Dis (2011) 1.64
Vector control by insecticide-treated nets in the fight against visceral leishmaniasis in the Indian subcontinent, what is the evidence? Trop Med Int Health (2008) 1.63
Effect of village-wide use of long-lasting insecticidal nets on visceral Leishmaniasis vectors in India and Nepal: a cluster randomized trial. PLoS Negl Trop Dis (2010) 1.61
A global comparative evaluation of commercial immunochromatographic rapid diagnostic tests for visceral leishmaniasis. Clin Infect Dis (2012) 1.59
Implementation research to support the initiative on the elimination of kala azar from Bangladesh, India and Nepal--the challenges for diagnosis and treatment. Trop Med Int Health (2008) 1.59
Mechanisms of experimental resistance of Leishmania to miltefosine: Implications for clinical use. Drug Resist Updat (2006) 1.58
Modular multiantigen T cell epitope-enriched DNA vaccine against human leishmaniasis. Sci Transl Med (2014) 1.57
Endocrine changes in male HIV patients. J Assoc Physicians India (2011) 1.56
Drug resistance in leishmaniasis. J Glob Infect Dis (2010) 1.52
Molecular mechanisms of antimony resistance in Leishmania. J Med Microbiol (2007) 1.50
Multilocus microsatellite typing (MLMT) reveals genetic homogeneity of Leishmania donovani strains in the Indian subcontinent. Infect Genet Evol (2008) 1.49
Serial quantitative PCR assay for detection, species discrimination, and quantification of Leishmania spp. in human samples. J Clin Microbiol (2011) 1.48
Sodium antimony gluconate induces generation of reactive oxygen species and nitric oxide via phosphoinositide 3-kinase and mitogen-activated protein kinase activation in Leishmania donovani-infected macrophages. Antimicrob Agents Chemother (2006) 1.48
Identification of genetic markers in sodium antimony gluconate (SAG) sensitive and resistant Indian clinical isolates of Leishmania donovani through amplified fragment length polymorphism (AFLP). Acta Trop (2009) 1.47
Efficacy and tolerability of miltefosine for childhood visceral leishmaniasis in India. Clin Infect Dis (2003) 1.46
IL-27 and IL-21 are associated with T cell IL-10 responses in human visceral leishmaniasis. J Immunol (2011) 1.44
Role of IL-10 and TGF-β in melanoma. Exp Dermatol (2015) 1.44
Options for active case detection of visceral leishmaniasis in endemic districts of India, Nepal and Bangladesh, comparing yield, feasibility and costs. PLoS Negl Trop Dis (2011) 1.42
Knowledge, attitude, and practices related to Kala-azar in a rural area of Bihar state, India. Am J Trop Med Hyg (2006) 1.40
A proteomics screen implicates HSP83 and a small kinetoplastid calpain-related protein in drug resistance in Leishmania donovani clinical field isolates by modulating drug-induced programmed cell death. Mol Cell Proteomics (2006) 1.36
Refractoriness to the treatment of sodium stibogluconate in Indian kala-azar field isolates persist in in vitro and in vivo experimental models. Parasitol Res (2005) 1.36
Phase 1 evaluation of intralesionally injected TLR9-agonist PF-3512676 in patients with basal cell carcinoma or metastatic melanoma. J Immunother (2008) 1.35
Cost-effectiveness analysis of combination therapies for visceral leishmaniasis in the Indian subcontinent. PLoS Negl Trop Dis (2010) 1.35
Costs of patient management of visceral leishmaniasis in Muzaffarpur, Bihar, India. Trop Med Int Health (2006) 1.35
Longitudinal seroepidemiologic study of visceral leishmaniasis in hyperendemic regions of Bihar, India. Am J Trop Med Hyg (2009) 1.34
Correlation between CD4 counts of HIV patients and enteric protozoan in different seasons - an experience of a tertiary care hospital in Varanasi (India). BMC Gastroenterol (2008) 1.34
Diarrhea, CD4 counts and enteric infections in a hospital - based cohort of HIV-infected patients around Varanasi, India. BMC Infect Dis (2006) 1.33
IL-10 neutralization promotes parasite clearance in splenic aspirate cells from patients with visceral leishmaniasis. J Infect Dis (2011) 1.33
Leishmania donovani suppresses activated protein 1 and NF-kappaB activation in host macrophages via ceramide generation: involvement of extracellular signal-regulated kinase. Infect Immun (2002) 1.32
The epidemiology of Leishmania donovani infection in high transmission foci in India. Trop Med Int Health (2010) 1.30
Measurement of recent exposure to Phlebotomus argentipes, the vector of Indian visceral Leishmaniasis, by using human antibody responses to sand fly saliva. Am J Trop Med Hyg (2010) 1.30
Characterization of natural antimony resistance in Leishmania donovani isolates. Am J Trop Med Hyg (2007) 1.29
Leishmania donovani affects antigen presentation of macrophage by disrupting lipid rafts. J Immunol (2005) 1.28
Drug susceptibility in Leishmania isolates following miltefosine treatment in cases of visceral leishmaniasis and post kala-azar dermal leishmaniasis. PLoS Negl Trop Dis (2012) 1.27
Antileishmanial activity of nano-amphotericin B deoxycholate. J Antimicrob Chemother (2008) 1.26
Evaluation of leishmanin skin test in Indian visceral leishmaniasis. Am J Trop Med Hyg (2009) 1.22
Reassessment of immune correlates in human visceral leishmaniasis as defined by cytokine release in whole blood. Clin Vaccine Immunol (2012) 1.20
Targeted killing of Leishmania donovani in vivo and in vitro with amphotericin B attached to functionalized carbon nanotubes. J Antimicrob Chemother (2011) 1.19
Case study for a vaccine against leishmaniasis. Vaccine (2013) 1.19
Miltefosine in the treatment of leishmaniasis: Clinical evidence for informed clinical risk management. Ther Clin Risk Manag (2007) 1.17
A phase II dose-ranging study of sitamaquine for the treatment of visceral leishmaniasis in India. Am J Trop Med Hyg (2005) 1.17
Persistence of Leishmania donovani antibodies in past visceral leishmaniasis cases in India. Clin Vaccine Immunol (2010) 1.16
Retraction: Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat Med (2003) 1.16
Latent infection with Leishmania donovani in highly endemic villages in Bihar, India. PLoS Negl Trop Dis (2013) 1.16
Designing therapies against experimental visceral leishmaniasis by modulating the membrane fluidity of antigen-presenting cells. Infect Immun (2009) 1.15
Inhibition of ABC transporters abolishes antimony resistance in Leishmania Infection. Antimicrob Agents Chemother (2007) 1.15
Common variants in the HLA-DRB1-HLA-DQA1 HLA class II region are associated with susceptibility to visceral leishmaniasis. Nat Genet (2013) 1.15
Diagnosis of Indian visceral leishmaniasis by nucleic acid detection using PCR. PLoS One (2011) 1.14
A multiattribute utility evaluation of different methods for the detection of enteric protozoa causing diarrhea in AIDS patients. BMC Microbiol (2010) 1.13
Evaluation of blood agar microtiter plates for culturing leishmania parasites to titrate parasite burden in spleen and peripheral blood of patients with visceral leishmaniasis. J Clin Microbiol (2010) 1.13
A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine for use in the prevention of visceral leishmaniasis. Vaccine (2011) 1.13
Population preference of net texture prior to bed net trial in Kala-Azar-endemic areas. PLoS Negl Trop Dis (2007) 1.13
Use of Leishmania donovani field isolates expressing the luciferase reporter gene in in vitro drug screening. Antimicrob Agents Chemother (2005) 1.12
Interferon-gamma release assay (modified QuantiFERON) as a potential marker of infection for Leishmania donovani, a proof of concept study. PLoS Negl Trop Dis (2011) 1.11
Study of parasite kinetics with antileishmanial drugs using real-time quantitative PCR in Indian visceral leishmaniasis. J Antimicrob Chemother (2011) 1.11
Characterisation of antimony-resistant Leishmania donovani isolates: biochemical and biophysical studies and interaction with host cells. Int J Parasitol (2011) 1.10
Detection of Leptomonas sp. parasites in clinical isolates of Kala-azar patients from India. Infect Genet Evol (2010) 1.09
Serological markers of sand fly exposure to evaluate insecticidal nets against visceral leishmaniasis in India and Nepal: a cluster-randomized trial. PLoS Negl Trop Dis (2011) 1.08
Chemokine-induced leishmanicidal activity in murine macrophages via the generation of nitric oxide. J Infect Dis (2002) 1.08
Asymptomatic Leishmania infection: a new challenge for Leishmania control. Clin Infect Dis (2014) 1.07
Antimony-resistant but not antimony-sensitive Leishmania donovani up-regulates host IL-10 to overexpress multidrug-resistant protein 1. Proc Natl Acad Sci U S A (2013) 1.07
CD8 T cell exhaustion in human visceral leishmaniasis. J Infect Dis (2013) 1.06
Visceral leishmaniasis in Muzaffarpur district, Bihar, India from 1990 to 2008. PLoS One (2011) 1.06
Elevated levels of tryparedoxin peroxidase in antimony unresponsive Leishmania donovani field isolates. Mol Biochem Parasitol (2010) 1.05
Memory and effector CD8 T-cell responses after nanoparticle vaccination of melanoma patients. J Immunother (2010) 1.04
Determinants of survival in adult HIV patients on antiretroviral therapy in Eastern Uttar Pradesh: a prospective study. Indian J Med Res (2014) 1.04
Intracellular survival of Leishmania species that cause visceral leishmaniasis is significantly reduced by HIV-1 protease inhibitors. J Infect Dis (2008) 1.03
Molecular docking, structure-activity relationship and biological evaluation of the anticancer drug monastrol as a pteridine reductase inhibitor in a clinical isolate of Leishmania donovani. J Antimicrob Chemother (2010) 1.03
Residual activity and integrity of PermaNet® 2.0 after 24 months of household use in a community randomised trial of long lasting insecticidal nets against visceral leishmaniasis in India and Nepal. Trans R Soc Trop Med Hyg (2011) 1.03
Leishmania donovani isolates with antimony-resistant but not -sensitive phenotype inhibit sodium antimony gluconate-induced dendritic cell activation. PLoS Pathog (2010) 1.03
Functionality of drug efflux pumps in antimonial resistant Leishmania donovani field isolates. Indian J Biochem Biophys (2009) 1.02
Comparative evaluation of freeze-dried and liquid antigens in the direct agglutination test for serodiagnosis of visceral leishmaniasis (ITMA-DAT/VL). Trop Med Int Health (2006) 1.02
HLA class I-restricted T cell epitopes of the kinetoplastid membrane protein-11 presented by Leishmania donovani-infected human macrophages. J Infect Dis (2007) 1.01